Drug EfficacySebetralstat delivers positive on-demand therapy for HAE with early symptom relief, signaling a potential shift in treatment preferences for patients.
Market OutlookAnalyst expects sebetralstat to become the first-line on-demand HAE treatment, indicating a positive outlook for the drug's commercial success.
Trial ResultsThe Phase 3 KONFIDENT trial of sebetralstat met all primary and key secondary endpoints, bolstering analyst confidence in its market potential.